IC
FNCH

Ikarian Capital’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Ikarian Capital’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,892
Closed -$18.1K – 162
2024
Q1 		$18.1K Hold
6,892
– – ﹤0.01% 134
2023
Q4 		$24.9K Hold
6,892
– – ﹤0.01% 130
2023
Q3 		$35.1K Sell
6,892
-1,025
-13% -$7.39K ﹤0.01% 133
2023
Q2 		$67.5K Sell
7,917
-1
-0% -$10 0.01% 119
2023
Q1 		$93.4K Hold
7,918
– – 0.02% 113
2022
Q4 		$114K Hold
7,918
– – 0.03% 78
2022
Q3 		$397K Sell
7,918
-3,099
-28% -$216K 0.08% 89
2022
Q2 		$938K Hold
11,017
– – 0.17% 79
2022
Q1 		$1.66M Buy
11,017
+493
+5% +$114K 0.22% 77
2021
Q4 		$3.15M Hold
10,524
– – 0.47% 48
2021
Q3 		$4.11M Sell
10,524
-309
-3% -$132K 0.29% 76
2021
Q2 		$4.57M Buy
10,833
+5,833
+117% +$2.52M 0.37% 71
2021
Q1 		$2.39M Buy
+5,000
New +$2.55M 0.08% 190

Other funds holding FNCH

LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital's FNCH Position: Q2 2024 in Review

Ikarian Capital sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2024, closing a stake of 6,892 shares — an estimated $18.1K sold.

Ikarian Capital first reported a position in FNCH in Q1 2021 and held it in 13 quarters. The position peaked at $4.57M in Q2 2021. 1 fund tracked by Wall St. Rank holds FNCH as of Q2 2024.

  • Ikarian Capital reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Ikarian Capital sold 6,892 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2024, an estimated $18.1K.
  • Ikarian Capital first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
  • Ikarian Capital's Finch Therapeutics Group, Inc. Common Stock position peaked at $4.57M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2024.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.